Sacituzumab tirumotecan
芦康沙妥珠单抗TROP2-directed ADC whose 2026 NRDL payment scope expands from 2 to 4 indications, adding HR+/HER2- breast cancer and earlier post-TKI EGFR-mutant NSCLC.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字S20240052
- Initial Approval Date
- Nov 27, 2024
- Notice Published
- Nov 27, 2024
- MAH
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (四川科伦博泰生物医药股份有限公司)
- Approved Scope
- Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting).
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #284 · Class B
- Agreement Period
- 2027-01-01 to 2027-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Expanded to 4 indications: (1) ≥3L TNBC; (2) HR+/HER2- unresectable/metastatic BC post-ET and ≥1L chemo; (3) EGFR-mutated non-squamous NSCLC post-EGFR-TKI and platinum chemo; (4) Earlier-line EGFR-mutated non-squamous NSCLC post-EGFR-TKI alone.
- 限:1.既往至少接受过2种系统治疗的不可切除局部晚期或转移性三阴性乳腺癌成人患者;2.既往接受过内分泌治疗且在晚期阶段接受过至少一线化疗的不可切除或转移性HR阳性HER2阴性(IHC 0、1+或2+/ISH-)乳腺癌成人患者;3.经EGFR-TKI和含铂化疗进展的EGFR突变阳性非鳞状NSCLC;4.经EGFR-TKI治疗后进展的EGFR突变阳性非鳞状NSCLC成人患者。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
2025 vs 2026 NRDL Payment Scope Comparison
Restricted to 2 indications: (1) ≥3L unresectable/metastatic TNBC; (2) EGFR-mutated locally advanced/metastatic non-squamous NSCLC after both EGFR-TKI and platinum-based chemotherapy.
限:1.既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者;2.经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。
Expanded to 4 indications: (1) ≥3L TNBC; (2) HR+/HER2- unresectable/metastatic BC post-ET and ≥1L chemo; (3) EGFR-mutated non-squamous NSCLC post-EGFR-TKI and platinum chemo; (4) Earlier-line EGFR-mutated non-squamous NSCLC post-EGFR-TKI alone.
限:1.既往至少接受过2种系统治疗的不可切除局部晚期或转移性三阴性乳腺癌成人患者;2.既往接受过内分泌治疗且在晚期阶段接受过至少一线化疗的不可切除或转移性HR阳性HER2阴性(IHC 0、1+或2+/ISH-)乳腺癌成人患者;3.经EGFR-TKI和含铂化疗进展的EGFR突变阳性非鳞状NSCLC;4.经EGFR-TKI治疗后进展的EGFR突变阳性非鳞状NSCLC成人患者。
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字S20240052 | Powder for Injection (注射剂) 200mg/瓶 | Initial Approval Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting). 用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。 | Approved: 2024-11-27 Published: 2024-11-27 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Payment Scope Updated
Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC.
Chinese original: 支付范围由2025版2项扩增至4项,新增HR+/HER2-乳腺癌及经EGFR-TKI治疗进展后的EGFR突变非鳞状NSCLC(无需先经含铂化疗)。
NHSA · PDF p.147Verified 2026-11-20 - (2024-11-27)NMPA Approval
NMPA Initial Marketing Approval (国药准字S20240052 · 200mg/瓶)
Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting).
Chinese original: 用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。
NMPA · NMPA Approval Announcement 2024-11-27Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07国家基本医疗保险、生育保险和工伤保险药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药监局药品监管动态Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20